Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35489377/
Collaborators, Affiliations 1 University of California, San Francisco, San Francisco, CA, USA. Electronic address: [email protected]. 2 University of Alabama at Birmingham, Birmingham, AL, USA. 3 Frontier Science & Technology and Research Foundation, Brookline, MA, USA. 4 Frontier Science & Technology and Research Foundation, Brookline, MA, USA; Harvard T H Chan School of Public Health, Boston, MA, USA.
Interpretation: In this study, the proposed once daily dosing of dolutegravir dispersible tablets provided drug exposures similar to those for adults, and was safe and well tolerated. These data support the use of dolutegravir dispersible tablets as first-line or second-line treatment for infants and children aged less than 6 years living with HIV-1.